Future of ADCs and targeted therapies in bladder cancer
Neeraj Agarwal shared a post on X:
“Future of ADCs and targeted therapies in bladder cancer comprehensive talk by Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center at the WorldGU24.
Novel inhibitors of Nectin-4, HER-2, TROP-2 (datopotamab), pan FGFR (Loxo-425, Tyra-300) and more.”
Source: Neeraj Agarwal/X
Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.
